Webinar Replay Available!

Prof You Li, shared his insights on RSV disease burden during the COVID-19 pandemic.

News updates

Recording Webinar Available!

“RSV disease burden during the COVID-19 pandemic”

Prof. You Li is a professor of epidemiology at Nanjing Medical University, China and an honorary fellow at University of Edinburgh, UK. He leads the Infectious Diseases Epidemiology and Modelling (IDEM) group at Nanjing Medical University. The group conducts research on disease burden, transmission, and prediction of respiratory infectious diseases as well as assessment of the impact of pharmaceutical and non-pharmaceutical interventions.

Paper of the Month: June 2024

Extremely high costs for RSV paediatric intensive care hospitalisation in the Netherlands.

 Authors: Emily Phijffer et al.

The implementation of the approved respiratory syncytial virus (RSV) preventive interventions in immunisation programmes is advancing rapidly. Insight into healthcare costs of RSV-related paediatric intensive care unit (PICU) admissions is lacking, but of great importance to evaluate the impact of implementation.

RSVVW’24 Conference

RSVVW’24 Conference!

Recap of the conference, explore the impressive video.

Conference photos!

Reflecting on the conference, explore the photos.

RSV Rewind!

A candid discussion on the highlights of RSVVW ‘24

In this E-Learning Professor Federico Martinón-Torres, Natalie Mazur, Jonne Terstappen and Prof. Louis Bont reflecting back on the RSVVW’24 Conference in Mumbai, India. This e-learning discusses new data, but also the consequences and challenges of RSV worldwide, for both children and older adults.

Article by IHI “Going viral: A new way to track RSV awareness”

We are happy to announce the release of an interesting article, authored by the experts of the IHI – Innovative Health Initiatives hedding light on our online RSV awareness tool.

RSV Dashboard 

We are proud to announce we have developed the first-ever global RSV surveillance dashboard and it is now live!

ReSViNET Foundation, in collaboration with AstraZeneca, is supporting healthcare decisions by providing transparency and accessibility to shared global RSV surveillance data. ReSViNET provides the first online and free dashboard about RSV. The dashboard simplifies tracking changes in RSV seasonality globally and includes at least 20 countries that are representative of different geographic regions from both hemispheres.

Connecting research and society

The ReSViNET Foundation is the first and leading global non-profit organisation fully committed to reducing the global burden of the Respiratory Syncytial Virus (RSV).

We collaborate with various stakeholders, such as researchers, the health sector, governments, international statutory bodies, non-profit organisations and the general public to raise awareness about RSV. Together, we address the challenges of prevention and treatment.

A global health challenge

Every year, Respiratory Syncytial Virus (RSV) affects more than 33 million children under 5 years worldwide. It is one of our most significant global healthcare challenges, not only in infants, but also in older adults. ReSViNET is the first official RSV foundation and aims to provide a platform for global collaborations to raise awareness about RSV infection and stimulate the development of RSV prevention and treatment.